AZD1208

SYN-1214



(5Z)-5-[[2-[(3R)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione

CAS Registry No.: 1204144-28-4

Smiles String:
C1CC(CN(C1)C2=C(C=CC=C2C=C3C(=O)NC(=O)S3)C4=CC=CC=C4)N

Molecular Weight: 379.48

Molecular Formula: C21H21N3O2S

Lot Number: Refer to vial

1H-NMR: Available on request

HPLC (Purity): > 95.0% @ 254 nm

ES-MS: Available on request

Description:

AZD1208 is a potent, highly selective, and orally available Pim kinase inhibitor that effectively inhibits all three isoforms at <5nM or <150 nM in enzyme and cell assays, respectively. Upregulation of Pim kinases is observed in several types of leukemias and lymphomas. Pim-1, -2, and -3 promote cell proliferation and survival downstream of cytokine and growth factor signaling pathways. AZD1208 also potently inhibits colony growth and Pim signaling substrates in primary AML cells from bone marrow that are Flt3 wild-type or Flt3 internal tandem duplication mutant.

Biological Activity



Kinome Mapping



Shipping and Storage Temperature

Shipping:
Ambient

Storage:
3 Months at -4C, >2 Years at -20C

Solubility

DMSO 75 mg/mL (with heating)

Preparing Stock Solutions

Stock Solution (1ml DMSO)	1mM	10mM	20mM	50mM
Mass(mg)	0. 379	3.795	7.590	18.974

References

1. Dakin LA, Block MH, Chen H, Code E, Dowling JE, Feng X, Ferguson AD, Green I, Hird AW, Howard T, Keeton EK, Lamb ML, Lyne PD, Pollard H, Read J, Wu AJ, Zhang T, Zheng X. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4599-604. doi: 10.1016/j.bmcl.2012.05.098. Epub 2012 Jun 6. PubMed PMID: 22727640.
2. Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur S, Wang S, Chen Y, Wu A, Shen M, Gibbons FD, Lamb ML, Zheng X, Stone RM, Deangelo DJ, Platanias LC, Dakin LA, Chen H, Lyne PD, Huszar D. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 6;123(6):905-13. doi: 10.1182/blood-2013-04-495366. Epub 2013 Dec 20. PubMed PMID: 24363397; PubMed Central PMCID: PMC3916880.
3. http://pubchem.ncbi.nlm.nih.gov//compound/58423153

Ordering Information

To order more of this or any other SYNkinase compound, go to synkinase.com, Call us Toll Free (US Only) at 1- 877-854-6273 or email orders@synkinase.com.